Efficacy and safety of levosimendan on patients with acute left heart failure in acute myocardial infarction
10.3760/cma.j.issn.1008-6315.2014.01.016
- VernacularTitle:左西孟旦治疗急性心肌梗死左心力衰竭患者的效果观察
- Author:
Xihong ZUO
;
Yanling ZHANG
;
Huan CHEN
- Publication Type:Journal Article
- Keywords:
Acute myocardial infarction;
Heart failure;
Levosimendan;
Dyspnea score;
Score general clinical condition;
Left ventricular ejection fraction;
Plasma N terminal B type natriuretic peptide;
Cardiac stroke volume
- From:
Clinical Medicine of China
2014;30(1):52-54
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of levosimendan on patients with acute left heart failure in acute myocardial infarction.Methods Thirty patients with acute left heart failure in acute myocardial infarction were selected and treated with an initial loading dose of levosimendan of 0.05 μg/(kg · min),followed increasing dose to 0.20 μg/(kg · min) for 24 h after no adverse reactions were observed.Clinical assessment was performed to evaluate efficacy and safety of levosimendan.Results The scores of dyspnea before medication was (1.95 0.71),(1.49 ±0.56) scores at 24 hours after medication and (1.15 ±0.51) scores at 1 week after medication group,and the differences were significant(F =3.346,P=0.043).The scores of clinical manifestation was also different among before medication group ((1.87 ±-1.21) scores),24 hours after medication group((1.36 ± 0.61) scores) and 1 week after medication group ((1.09 ± 0.58) scores,F =5.203,P =0.024).After 1 week medication left ventricular ejection fraction (LVEF),stroke volume (SV) and plasma NT-proBNP had significant difference with before medication group (LVEF:before medication group:(30.41 ± 5.62) ％,1 week group:(43.16 ± 8.51) ％,t =2.238,P =0.037 ;SV:before medication group:(59.52 ± 25.23) ml,1 week group:(72.31 ± 14.91) ml,t =2.067,P =0.047 ;BNP:before medication group:(2 534.56 ± 1 570.23) rng/L,1 week group:(934.32 ± 421.53) ng/L,t=2.347,P =0.020).No severe adverse effects were seen during the course of medication,while the common adverse effects including palpitations,dizziness,hypotension and ventricular premature beats were remission after treatment.Conclusion Levosimendan treatment on acute myocardial infarction,heart failure is proved to be an efficacy,safety,and well tolerated.
